. "Alzheimer`s disease; cholinesterase inhibitors; donepezil; galantarnine; rivastigmine; safety, efficacy"@en . . "The article brings current insight into the efficacy and safety of cholinesterase inhibitors in the treatment of dementia, focusing on two phases of administration - an initial dose-escalation phase to achieve a therapeutic dose and a maintenance phase where the therapeutic dose is given for long-term therapy Cholinesterase inhibitors are associated with a range of side effects as a result of cholinergic stimulation in different areas of the brain and the periphery. The appearance of side effects depends on the treatment phase and also on the type of inhibitor."@en . "504774" . "Farmakoterapie" . "1801-1209" . . . "RIV/00023752:_____/06:00000519" . "\u00DA\u010Dinnost a bezpe\u010Dnost pod\u00E1v\u00E1n\u00ED inhibitor\u016F cholinester\u00E1z" . . . "\u00DA\u010Dinnost a bezpe\u010Dnost pod\u00E1v\u00E1n\u00ED inhibitor\u016F cholinester\u00E1z"@cs . "1"^^ . . "1"^^ . "\u00DA\u010Dinnost a bezpe\u010Dnost pod\u00E1v\u00E1n\u00ED inhibitor\u016F cholinester\u00E1z"@cs . "CZ - \u010Cesk\u00E1 republika" . . "\u010Cl\u00E1nek p\u0159in\u00E1\u0161\u00ED sou\u010Dasn\u00FD pohled na \u00FA\u010Dinnost a bezpe\u010Dnost pod\u00E1v\u00E1n\u00ED inhibitor\u016F cholinester\u00E1zy u pacient\u016F s demenc\u00ED. Pozornost je v\u011Bnov\u00E1na dv\u011Bma f\u00E1z\u00EDm pod\u00E1v\u00E1n\u00ED - inic\u00E1ln\u00ED eskala\u010Dn\u00ED f\u00E1ze, kter\u00E1 slou\u017E\u00ED k dosa\u017Een\u00ED pot\u0159ebn\u00E9 terapeutick\u00E9 d\u00E1vky a udr\u017Eovac\u00ED f\u00E1ze, b\u011Bhem kter\u00E9 je terapeutick\u00E1 d\u00E1vka pod\u00E1v\u00E1na dlouhodob\u011B. L\u00E9\u010Dba inhibitory cholinester\u00E1zy je spojena s \u0159adou vedlej\u0161\u00EDch \u00FA\u010Dink\u016F, plynouc\u00EDch z cholinergn\u00ED stimulace r\u016Fzn\u00FDch oblast\u00ED mozku a periferie. V\u00FDskyt t\u011Bchto vedlej\u0161\u00EDch \u00FA\u010Dink\u016F z\u00E1vis\u00ED na f\u00E1ze l\u00E9\u010Dby a tak\u00E9 na typu u\u017E\u00EDvan\u00E9ho inhibitoru."@cs . "Brunovsk\u00FD, Martin" . "3" . "The efficacy and safety of cholinesterase inhibitors"@en . "343-349" . . . . . "P(1A8600), P(1M0517)" . . "RIV/00023752:_____/06:00000519!RIV07-MZ0-00023752" . "\u00DA\u010Dinnost a bezpe\u010Dnost pod\u00E1v\u00E1n\u00ED inhibitor\u016F cholinester\u00E1z" . . . . . . "\u010Cl\u00E1nek p\u0159in\u00E1\u0161\u00ED sou\u010Dasn\u00FD pohled na \u00FA\u010Dinnost a bezpe\u010Dnost pod\u00E1v\u00E1n\u00ED inhibitor\u016F cholinester\u00E1zy u pacient\u016F s demenc\u00ED. Pozornost je v\u011Bnov\u00E1na dv\u011Bma f\u00E1z\u00EDm pod\u00E1v\u00E1n\u00ED - inic\u00E1ln\u00ED eskala\u010Dn\u00ED f\u00E1ze, kter\u00E1 slou\u017E\u00ED k dosa\u017Een\u00ED pot\u0159ebn\u00E9 terapeutick\u00E9 d\u00E1vky a udr\u017Eovac\u00ED f\u00E1ze, b\u011Bhem kter\u00E9 je terapeutick\u00E1 d\u00E1vka pod\u00E1v\u00E1na dlouhodob\u011B. L\u00E9\u010Dba inhibitory cholinester\u00E1zy je spojena s \u0159adou vedlej\u0161\u00EDch \u00FA\u010Dink\u016F, plynouc\u00EDch z cholinergn\u00ED stimulace r\u016Fzn\u00FDch oblast\u00ED mozku a periferie. V\u00FDskyt t\u011Bchto vedlej\u0161\u00EDch \u00FA\u010Dink\u016F z\u00E1vis\u00ED na f\u00E1ze l\u00E9\u010Dby a tak\u00E9 na typu u\u017E\u00EDvan\u00E9ho inhibitoru." . . "The efficacy and safety of cholinesterase inhibitors"@en . . "7"^^ . "2" . "[A16FF78B5EA0]" .